/AMGEN%20Inc_%20logo%20on%20phone-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
Amgen Inc. (AMGN) is a leading biotechnology company headquartered in Thousand Oaks, California. It specializes in the discovery, development, manufacturing, and delivery of innovative human therapeutics, particularly biologics that target serious illnesses such as cancer, cardiovascular disease, inflammation, and bone disorders. Amgen pioneered recombinant DNA technology to advance patient care globally. The company has a market capitalization of $184.10 billion.
The stock has been facing solid investor sentiment. Over the past 52 weeks, Amgen’s stock has gained 20.4%, while over the past six months, it has risen 13.4%. The company’s shares reached a 52-week high of $353.25 on Jan. 27, but are down 3.2% from that level.